Contents 1 Pinyin 2 English reference 3 Overview 4 Common name 5 English name 6 Synonyms of Qianpilin 7 Classification 8 Pharmacological effects of Qianpilin 9 Pharmacokinetics of Qianpilin 10 Qianpilin’s Indications 11 Contraindications of Qianpilin 12 Precautions 13 Adverse reactions of Qianpilin 14 Dosage forms and specifications of Qianpilin 15 Usage and dosage of Qianpilin 16 Interactions between Qianpilin and other drugs 17 Clinical aspects of Qianpilin Application 18 Amoxicillin poisoning 18.1 Clinical manifestations 18.2 Treatment 19 Pharmacopoeia standards of amoxicillin 19.1 Product name 19.1.1 Chinese name 19.1.2 Chinese Pinyin 19.1.3 English name 19.2 Structural formula 19.3 Molecular formula and molecular weight 19.4 Source (name), content (effect Price) 19.5 Properties 19.5.1 Specific rotation 19.6 Identification 19.7 Inspection 19.7.1 Acidity 19.7.2 Clarity of solution 19.7.3 Related substances 19.7.4 Amoxicillin polymer 19.7.4.1 Chromatographic conditions and system suitability test 19.7. 4.2 Preparation of control solution 19.7.4.3 Determination method 19.7.5 Residual solvent 19.7.6 Moisture 19.7.7 Ignition residue 19.8 Content determination 19.8.1 Chromatographic conditions and system suitability test 19.8.2 Determination method 19.9 Category 19.10 Storage 19.11 Preparation 19.12 Version 20 References This is a redirect entry sharing amoxicillin content. For the convenience of reading, amoxicillin in the following text has been automatically replaced by Qianbilin. You can click here to restore the original appearance, or use the note method to display 1 Pinyin
qiáng bì lín 2 English reference
Amoxcillin 3 Overview
Amoxcillin is a semi-synthetic broad-spectrum penicillin, belonging to the beta-lactam antibiotics and aminopenicillins. It is white or off-white crystalline powder; tastes slightly bitter. Its antibacterial mechanism is the same as penicillin, its antibacterial spectrum is similar to ampicillin, its antibacterial effect is slightly stronger than ampicillin, but its effect on enterococci and salmonella is stronger than ampicillin. It is not resistant to penicillinase, so it is ineffective against bacteria that easily produce penicillinase. It is used to treat typhoid fever, other salmonella infections and typhoid carriers, urinary tract infections caused by sensitive bacteria, and leptospirosis caused by pneumococci, non-penicillinase-producing Staphylococcus aureus, hemolytic streptococci, and influenza bacilli. Well absorbed orally.
Qianbilin is a national essential drug. 4 Common name
Amoxicillin
5 English name
Amoxicillin 6 Alias ??of Amoxicillin
Amoxicillin; Ling; Amoxin; Amoxin; Amoxicillin; Onaxin; Phenotacillin; Fremoxin; Netamide; Amoxicillin; Amoxicillin Power; Amoxicillin; Trix; Xindabenin ; Amoxicillin trihydrate 7 Classification
Antimicrobial drugs> β-lactam antibiotics?> Penicillins>? Semi-synthetic penicillins 8 Pharmacological effects of Qianpilin
Qianpilin For Streptococcus pneumoniae, hemolytic Streptococcus and other Streptococci, non-penicillinase-producing Staphylococcus aureus, Enterococcus faecalis and other aerobic Gram-positive cocci, Escherichia coli, Proteus mirabilis, Salmonella, Haemophilus influenzae and Non-β-lactamase-producing strains of aerobic Gram-negative bacteria such as Neisseria gonorrhoeae and Helicobacter pylori have good antibacterial activity. The antibacterial spectrum is the same as that of ampicillin, but it is acid-resistant and has strong bactericidal effect. Qianbilin and ampicillin have complete cross-resistance. [1]
The acid resistance of strongwill is stronger than that of ampicillin (the same amount of the drug is taken orally, and the blood concentration is twice as high as that of ampicillin). Its bactericidal effect is better than ampicillin, especially its bactericidal effect on certain Streptococcus and Salmonella species is stronger than ampicillin.
Jambilin is effective against penicillin-sensitive Gram-positive bacteria; Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Salmonella spp., Shigella dysenteriae, Neisseria meningitidis and Gram-negative bacteria such as Neisseria gonorrhoeae that do not produce enzymes have strong antibacterial activity; they have certain antibacterial activity against some Escherichia coli, Legionella and Campylobacter fetus; in addition, they are also effective against Leptospira and Treponema pallidum. role. Most Shigella, most Enterobacteriaceae, Bacteroides fragilis, Pseudomonas aeruginosa, etc. are resistant to Qianbilin.
9 Pharmacokinetics
Jianbilin is rapidly absorbed after oral administration, 75% to 90% can be absorbed through the gastrointestinal tract, and the peak time is about 2 hours. It is widely distributed, with an apparent distribution volume of 0.41L/kg and a plasma protein binding rate of 17% to 20%. It can pass through the placenta, and the concentration in the umbilical cord blood is 1/4 to 1/3 of the maternal blood concentration. Drug concentrations are extremely low in breast milk, sweat, and tears. [1]
The elimination half-life is 1 to 1.3 hours; in patients with severe renal insufficiency, the half-life can be extended to about 7 hours. After a single oral administration of 0.25g and 0.5g, 24% and 33% of the administered dose are metabolized in the liver respectively [1].
About 60% of the oral dose is excreted in unchanged form through the kidneys and feces within 6 hours; 20% of the oral dose is excreted in the urine as penicillin; some other drugs can be excreted in the bile excretion. Hemodialysis can remove some drugs, but peritoneal dialysis cannot remove prednisolone. [1]
The peak plasma concentrations after oral administration of 0.25, 0.5 and 1g are 5.1, 10.8 and 20.6μg/ml respectively, and the peak time is approximately 2 hours.
The peak plasma concentration of 500 mg of strongbilline sodium injected intramuscularly is 14 μg/ml, which is similar to the peak concentration of the same dose taken orally, and the peak time is about 1 hour.
After intravenous injection of 500 mg of strong bifurcation sodium, the blood concentration was 42.6 μg/ml after 5 minutes and 1 μg/ml after 5 hours.
The drug is widely distributed after absorption, with a distribution volume of 0.41L/kg.
Jambilin can pass through the placenta, and the concentration in the umbilical cord blood is 1/4 to 1/3 of the maternal blood concentration. Drug concentrations are extremely low in breast milk, sweat, and tears.
For patients with acute onset of pneumonia or chronic bronchitis, the average drug concentration in sputum after 2 to 3 or 6 hours was 0.52 μg/ml and 0.53 μg/ml respectively. The plasma drug concentration during the same period was They are 11μg/ml and 3.5μg/ml respectively.
Children with chronic otitis media take 1g orally, and the drug concentration in the middle ear fluid after 1 to 2 hours is 6.2μg/ml.
Patients with tuberculous meningitis take 1.0g orally, and the drug concentration in the cerebrospinal fluid after 2 hours is 0.1 to 1.5 μg/ml, which is equivalent to 0.9% to 21.1% of the blood drug concentration in the same period. After intravenous injection of 2g, the drug concentration in the cerebrospinal fluid reaches 2.9-40.0μg/ml 1.5 hours later, which is about 8%-93% of the blood drug concentration.
The drug concentration in urine is very high. After oral administration of 250mg, the drug concentration in urine is as high as 0.3~1.3mg/ml.
The protein binding rate of prednisone is 17% to 20%, and the half-life is 1.0 to 1.3 hours, which can be extended to 5 to 20 hours in patients with severe renal insufficiency. 10 Indications
Jianbilin is used for respiratory tract, urinary tract and biliary tract infections caused by sensitive bacteria, typhoid fever, leptospirosis, etc. Triple therapy with clarithromycin and omeprazole (or other proton pump inhibitors) can be used to eradicate Helicobacter pylori from the stomach and duodenum. [1]
1. People with typhoid fever, other salmonella infections and typhoid fever carriers.
2. Lower urinary tract infection caused by sensitive bacteria, non-enzyme-producing gonococcal urethritis, non-specific urethritis (cervicitis), etc.
3. Ear, nose and throat infections, respiratory tract infections and soft tissue infections caused by Streptococcus pneumoniae, non-penicillinase-producing Staphylococcus aureus, hemolytic Streptococcus and influenza bacilli.
4. Leptospirosis. 11 Contraindications
It is contraindicated in those allergic to strongbilline or other penicillins [1].
Patients with infectious mononucleosis, cytomegalovirus infection, lymphocytic leukemia, lymphoma, etc. who use strongbilline may cause rashes and should avoid its use. [1] 12 Precautions
Same as penicillins. Food can delay the absorption of prednisolone, but it does not affect the total drug absorption. To reduce gastrointestinal reactions, it should be taken after meals. [1] 13 Adverse reactions
The adverse reactions of Qianbilin are the same as those of other penicillins. Common gastrointestinal reactions after oral administration include nausea, vomiting and diarrhea, and occasionally pseudomembranous colitis. [1]
Common allergic reactions to penicillin include severe anaphylactic shock and serological reactions, leukopenia, drug rash, contact dermatitis and asthma attacks. Toxic reactions are rare when administered at low doses. Peripheral neuritis can occur at the site of intramuscular injection. Intrathecal injection of more than 20,000 units or intravenous infusion of large doses can cause convulsions, myoclonus, and lethargy. It can also cause temporary mental disorder, which can be recovered by stopping the drug or reducing the dose. Long-term medication can cause secondary infections, such as penicillin-resistant Staphylococcus aureus, Gram-negative bacilli or Candida infections. [2]
The overall incidence of adverse reactions in clinical application of Qianbilin is 5% to 6%, and about 2% require drug discontinuation.
1. Gastrointestinal symptoms such as diarrhea, nausea, and vomiting are relatively common, accounting for about 3.1%.
2. Allergic reaction symptoms such as rash, drug fever, and asthma are also common. It is especially likely to occur in patients with infectious mononucleosis.
3. A few patients occasionally suffer from liver and kidney toxicity (abnormal liver function, acute interstitial nephritis, etc.) after taking the drug.
4. A few patients occasionally experience increased eosinophils and decreased leukocytes after taking the drug.
5. Long-term, high-dose medication can cause bacterial imbalance and secondary infection caused by Candida or drug-resistant bacteria. 14 Dosage forms and specifications
Tablets, capsules, granules, dry suspension: ①0.125g; ②0.25g. [1]. 15 Usage and Dosage of Jianbilin
Oral administration [1].
(1) Adults: 0.5g once, once every 6 to 8 hours. The daily dose should not exceed 4g. If the creatinine clearance rate is 10-30ml/min, take 0.25-0.5g once every 12 hours; if the creatinine clearance rate is less than 10ml/min, take 0.25-0.5g once every 24 hours. [1]
(2) Children: ① Children over 3 months old: 25 to 50 mg/kg per day, once every 8 hours. ②Infants under 3 months: 30 mg/kg per day, once every 12 hours. [1] 16 Drug interactions
(l) Combined use with probenecid, aspirin, indomethacin and sulfonamides can reduce the excretion of prednisolone, prolong its half-life, and increase its plasma concentration. [1].
Probenecid can delay the renal excretion of prednisolone and increase the blood concentration of the drug.
(2) Combined use with allopurine uric acid synthesis inhibitors increases the risk of adverse skin reactions [1].
Allopurinol can increase the incidence of skin and mucosal adverse reactions of strongbiline.
(3) Combination with methotrexate can increase the toxicity of methotrexate [1].
Prednisolone may decrease the renal clearance of methotrexate, thereby increasing methotrexate toxicity.
(4) Taking birth control pills at the same time may affect the contraceptive effect [1].
When used together with contraceptive pills, Qianbilin can inhibit the metabolism of estrogen or reduce its enterohepatic circulation, reducing the efficacy of oral contraceptives.
(5) When combined with β-lactamase inhibitors such as clavulanic acid, the antibacterial effect is significantly enhanced. Clavulanic acid not only enhances the sensitivity of beta-lactamase-producing strains to prednisolone, but also enhances the effect of prednisolone against certain non-susceptible strains, including Bacteroidetes, Legionella, Nocardia, and Pseudomonas aeruginosa. Bacillus anthracis.
(6) Strongbiline can weaken the immune response produced by live typhoid vaccine. The possible mechanism is that strongbiline has antibacterial activity against Salmonella typhi. 17 Clinical Application of Qianpilin
It is reported that Qianpilin can achieve satisfactory efficacy in the treatment of typhoid fever, other Salmonella infections and typhoid carriers. Its clinical results, bacteriological clearance rate and body temperature in the treatment of typhoid fever The response is better than that of chloramphenicol; satisfactory curative effect can also be obtained in the treatment of urinary tract infections caused by sensitive bacteria. For patients whose infection is limited to the lower urinary tract, a single dose of 3g can obtain satisfactory curative effect. Qianbilin can be used for infections of the facial features, skin and soft tissues caused by pneumococci, non-penicillinase-producing Staphylococcus aureus, hemolytic streptococci, and influenza bacilli. It can be used in combination with H2 receptor antagonists or proton pump inhibitors for gastritis and duodenal ampulla ulcers caused by Helicobacter pylori. 18 Jianbilin poisoning
Jianbilin (ampicillin) is used to treat typhoid fever, other salmonella infections and typhoid carriers, urinary tract infections caused by sensitive bacteria, and pneumococci and non-penicillinase-producing bacteria. Leptospirosis caused by Staphylococcus aureus, hemolytic Streptococcus, and influenzae bacteria. It is well absorbed orally, with a protein binding rate of 17% to 20% and a half-life of 1 to 1.3 hours. In advanced renal failure, the half-life can be extended to 5 to 20 hours. The usual dosage is 0.5~1.0g, 3/d, orally. [3] 18.1 Clinical manifestations
[3]
1. Common adverse reactions are gastrointestinal symptoms such as diarrhea, nausea, and vomiting, which are more common, accounting for about 3.1%.
2. The incidence of rash is about 2%. Drug fever and asthma also occur. Individually, serum aminotransferase increases. Occasionally, eosinophils increase and granulocytopenia occurs. 18.2 Treatment
The key points in the treatment of strongbilline poisoning are [3]:
1. See the related content of penicillin.
2. Hemodialysis can remove products from the blood, but peritoneal dialysis is ineffective. 19 Pharmacopoeia standard of Qianpilin 19.1 Product name 19.1.1 Chinese name
Qianpilin 19.1.2 Chinese Pinyin
Amoxilin 19.1.3 English name
Amoxicillin 19.2 Structural formula 19.3 Molecular formula and molecular weight
C16H19N3O5S·3H2O 419.46 19.4 Source (name), content (potency)
This product is (2S, 5R, 6R) 3,3 dimethyl Base 6[(R)(-)2amino2(4hydroxyphenyl)acetamido]7oxo4thia1azabicyclo[3.2.0]heptane2carboxylic acid trihydrate.
Calculated as anhydrous, the content of C16H19N3O5S shall not be less than 95.0%. 19.5 Properties
This product is white or off-white crystalline powder; tastes slightly bitter. This product is slightly soluble in water and almost insoluble in ethanol. 19.5.1 Specific rotation
Take this product, weigh it accurately, add water to dissolve and quantitatively dilute it to make a solution containing about 2mg per 1ml, and measure it according to the law (Appendix VI E of Part II of the Pharmacopoeia 2010 edition). Specific rotation is +290° to +315°. 19.6 Identification
(1) Take about 0.125g each of this product and the reference substance of Strongbilline, add 4.6% sodium bicarbonate solution respectively to dissolve and dilute to make a solution containing about 10mg of Strongbiline per 1ml. , as the test solution and reference solution; in addition, take an appropriate amount of each of the prednisolone reference substance and the cefazolin reference substance, add 4.6% sodium bicarbonate solution to dissolve and dilute it to make each 1ml containing approximately 10 mg of prednisolone and cefazolin. A solution of 5 mg of oxazoline was used as the system suitability test solution. According to the thin layer chromatography test (Appendix V B of the 2010 edition of the Pharmacopoeia Part 2), take 2 μl of each of the above three solutions and spot them on the same silica gel GF254 thin layer plate. Use ethyl acetate-acetone-glacial acetic acid-water (5: 2:2:1) is the developing agent, unfold, dry, and inspect under UV lamp 254nm. The system suitability test solution should show two clearly separated spots. The position and color of the main spot displayed by the test solution should be the same as the position and color of the main spot of the reference solution.
(2) In the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
(3) The infrared light absorption spectrum of this product should be consistent with the control spectrum (Figure 441 of "Drug Infrared Spectrum Collection").
You can choose one of the above two items (1) and (2). 19.7 Inspection 19.7.1 Acidity
Take this product, add water to make a solution containing 2mg per 1ml, and measure it according to the law (2010 edition of the Pharmacopoeia, Appendix VI H). The pH value should be 3.5 to 5.5. 19.7.2 Clarity of solution
Take 5 parts of this product, 1.0g each, add 10ml of 0.5mol/L hydrochloric acid solution respectively, observe immediately after dissolution, take another 5 parts of this product, 1.0g each, Add 10ml of 2mol/L ammonia solution respectively and observe immediately after dissolving. The solution should be clear. If it is obviously turbid, it should not be more concentrated than the No. 2 turbidity standard solution (Appendix IX B of Pharmacopoeia, Part 2, 2010 Edition). 19.7.3 Related substances
Take an appropriate amount of this product, weigh it accurately, add mobile phase A to dissolve and quantitatively dilute it to make a solution containing about 2.0mg per 1ml, which will be used as the test solution; take another strong An appropriate amount of Bilin reference substance was accurately weighed, dissolved in mobile phase A and quantitatively diluted to prepare a solution containing approximately 20 μg per 1 ml, which was used as a control solution. Determine according to high performance liquid chromatography (2010 edition of Pharmacopoeia Part 2 Appendix V D), using octadecylsilane bonded silica gel as the filler; using 0.05mol/L phosphate buffer (take 0.05mol/L potassium dihydrogen phosphate solution, use 2mol/L potassium hydroxide solution to adjust the pH to 5.0) - acetonitrile (99:1) as the mobile phase A; use 0.05mol/L phosphate buffer (pH 5.0) acetonitrile (80:20) as the mobile phase B; Detection wavelength 254nm. First use mobile phase A and mobile phase B (92; 8) to elute isocraticly. After the elution of the strong bilin peak is completed, immediately follow the linear gradient elution shown in the table. Take an appropriate amount of the system suitability reference substance of Qianbilin, add mobile phase A to dissolve and dilute it to make a solution containing approximately 2.0 mg per 1 ml, take 20 μl and inject it into the liquid chromatograph. The recorded chromatogram should be consistent with the standard chromatogram. Take 20 μl of the control solution and inject it into the liquid chromatograph, and adjust the detection sensitivity so that the peak height of the main component chromatographic peak is approximately 25% of the full scale. Then accurately measure 20 μl each of the test solution and the control solution, inject them into the liquid chromatograph respectively, and record the chromatogram. If there is an impurity peak in the chromatogram of the test solution, the area of ??a single impurity peak shall not be greater than the main peak area of ??the control solution (1.0% ), the sum of the peak areas of each impurity shall not be greater than 3 times (3.0%) of the main peak area of ??the control solution, and any peak in the chromatogram of the test solution that is less than 0.05 times the main peak area of ??the control solution can be ignored. Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 92 8 25 0 100 40 0 ??100 41 92 8 55 92 8 19.7.4 Strongbilin polymer
According to size exclusion Determination by chromatography (2010 edition of Pharmacopoeia, Part II, Appendix V H). 19.7.4.1 Chromatographic conditions and system suitability test
Use Sephadex G10 (40~120μm) as filler, glass column inner diameter 1.0~1.4cm, column length 30~40cm, mobile phase A It is 0.05mol/L phosphate buffer with pH 8.0 (0.05mol/L disodium hydrogen phosphate solution-0.05mol/L sodium dihydrogenphosphate solution (95:5)], mobile phase B is water, and the flow rate is 1.5 per minute. ml, the detection wavelength is 254nm.
Measure 100 to 200 μl of 0.2 mg/ml blue dextran 2000 solution and inject it into the liquid chromatograph. Measure using mobile phases A and B as mobile phases, and record the chromatogram. The number of theoretical plates calculated based on the blue dextran 2000 peak should not be less than 500, and the tailing factor should be less than 2.0. The ratio of the retention times of the blue dextran 2000 peak in the two mobile phase systems should be between 0.93 and 1.07. The main peak of the control solution and the polymer peak in the test solution are related to the blue dextran 2000 peak in the corresponding chromatographic system. The ratio of retention times should be between 0.93 and 1.07. Weigh about 0.2g of Strongbilline into a 10ml measuring flask, add 4ml of 2% anhydrous sodium carbonate solution to dissolve, dilute to the mark with 0.3mg/ml blue dextran 2000 solution, and shake well. Measure 100 to 200 μl and inject it into the liquid chromatograph, measure with mobile phase A, and record the chromatogram. The peak height of the polymer and the valley height ratio between the monomer and the polymer should be greater than 2.0. In addition, use mobile phase B as the mobile phase, accurately measure 100 to 200 μl of the control solution, and inject the sample 5 times continuously. The relative standard deviation of the peak area should not be greater than 5.0%. 19.7.4.2 Preparation of control solution
Take an appropriate amount of penicillin reference substance, weigh it accurately, add water to dissolve and quantitatively dilute it to prepare a solution containing approximately 0.2mg per 1ml. 19.7.4.3 Determination method
Take about 0.2g of this product, weigh it accurately, put it in a 10ml measuring bottle, add 4ml of 2% anhydrous sodium carbonate solution to dissolve, dilute to the mark with water, shake well, and immediately Precisely measure 100 to 200 μl and inject it into the chromatograph, use mobile phase A as the mobile phase for measurement, and record the chromatogram. In addition, accurately measure 100 to 200 μl of the control solution and inject it into the chromatograph, using mobile phase B as the mobile phase, and measure in the same way. Calculate the peak area according to the external standard method, and divide the result by 10. Polymers containing strong bifurcation shall not exceed 0.15% based on strong bifurcation (presence of strong bifurcation: penicillin 1:10). Human body surface area calculator BMI index calculation and evaluation Female safe period calculator Pregnancy date calculator Normal weight gain during pregnancy Safety classification of medication during pregnancy (FDA) Five elements and eight characters Adult blood pressure evaluation Body temperature level evaluation Diabetes diet recommendations Common clinical biochemistry units Conversion to basal metabolic rate Calculate sodium supplementation calculator Iron supplementation calculator Commonly used Latin abbreviations for prescription Quick check Common symbols for pharmacokinetics Quick check Effective plasma osmolarity calculator Ethanol intake calculator
Medical encyclopedia, calculate now! 19.7.5 Residual solvent
Accurately weigh 0.25g of this product in acetone and methylene chloride, place it in a headspace bottle, accurately add 5ml of dimethylacetamide to dissolve, seal, and use it as the test solution; weigh accurately Take an appropriate amount of acetone and methylene chloride, add dimethylacetamide to quantitatively dilute it to prepare a solution containing approximately 40 μg of acetone and 30 μg of methylene chloride per 1 ml. Precisely measure 5 ml, place it in a headspace bottle, seal it, and use it as a reference solution. Determine according to the residual solvent determination method (2010 edition of the Pharmacopoeia, Appendix VIII P Second Method). A capillary column with 6% cyanopropylphenyl-94% dimethylpolysiloxane (or similar polarity) as the stationary solution is used as the chromatographic column; the initial temperature is 40°C, maintained for 4 minutes, and then at 30°C per minute. The temperature is increased to 200°C at a rate and maintained for 6 minutes; the inlet temperature is 300°C, and the detector temperature is 250°C; the equilibrium temperature of the headspace bottle is 80°C, and the equilibrium time is 30 minutes; take the reference solution for headspace injection , record the chromatogram, and the resolution of acetone and methylene chloride should meet the requirements. Inject headspace samples of the test solution and reference solution respectively, and record the chromatograms. According to the external standard method and calculated based on the peak area, the content of methylene chloride should not exceed 0.12%, and the content of acetone should comply with the regulations. 19.7.6 Moisture
Take this product and measure it according to the moisture determination method (Appendix VIII M, Method 1, 2010 edition of the Pharmacopoeia). The moisture content should be 12.0% to 15.0%. 19.7.7 Residue on ignition
Take 1.0g of this product and check it according to the law (2010 edition of Pharmacopoeia, Part II, Appendix VIII N). The residue left behind should not exceed 1.0%. 19.8 Content determination
Determine according to high performance liquid chromatography (Appendix V D of Pharmacopoeia Part 2, 2010 Edition). 19.8.1 Chromatographic conditions and system suitability test
Use octadecylsilane bonded silica gel as filler; use 0.05mol/L potassium dihydrogen phosphate solution (adjusted with 2mol/L potassium hydroxide solution pH value to 5.0)-acetonitrile (97.5:2.5) is the mobile phase; the detection wavelength is 254nm. Take about 25 mg of amoxicillin system suitability reference substance, put it in a 50 ml volumetric flask, dissolve it with mobile phase and dilute it to the mark, shake well, take 20 μl and inject it into the liquid chromatograph. The recorded chromatogram should be consistent with the standard chromatogram. 19.8.2 Determination method
Take about 25mg of this product, weigh it accurately, put it in a 50ml measuring bottle, add mobile phase to dissolve and dilute to the mark, shake well, accurately measure 20μl and inject it into the liquid chromatograph. Record the chromatogram; take an appropriate amount of prednisone reference substance and measure in the same way. It is calculated by the peak area according to the external standard method.
19.9 Category
Beta-lactam antibiotics, penicillins. 19.10 Storage
Shield from light and store in a sealed container.
19.11 Preparations
(1) Strongbiline dry suspension? (2) Strongbiline tablets (3) Strongbiline capsules? (4) Strongbiline granules Version 19.12